• Events
  • Road to Commercialization Symposium Series: Launching a Startup

Road to Commercialization Symposium Series: Launching a Startup

Date & Time

Tuesday, November 19, 2024, 10:00 a.m.-11:30 a.m.

Category

Information Session

Location

Zoom

Information

Note: Attendance counts towards a requirement for TechAdvance® or HealthAdvance® funding.

Infographic for Nov. 19 webinar Launching a Startup

Join us for the next webinar on the Road to Commercialization Symposium series!

The topic is Launching a Startup: When is the Right Time?

Thinking about launching your own start-up? Turning an idea or technology into your own startup is a challenging endeavor, involving intellectual property and legal requirements. Hear from a panel of experts, including startup founders and legal counsel, on the steps you should take when creating your own company. 

Panelists

headshot of Mark Ehrmann, partner at Quarles & Brady LLP

Mark Ehrmann, JD

Partner, Quarles & Brady LLP

Mark is a corporate lawyer who advises early-stage and maturing companies. With an unusual depth and breadth of transactional experience, Mark works on all sides of emerging and established businesses as outside corporate counsel, deal, finance and securities counsel advising research institutions that incubate startups, startup and emerging companies, and investors in startup and emerging companies.

headshot of Ken Suh, CEO of Sauvie Inc.

Ken Suh

CEO, Sauvie Inc.

Ken is a seasoned biopharmaceutical executive with over 22 years of experience, blending leadership roles at top multinational companies with executive positions in emerging biopharmaceutical firms. He is currently the founder and CEO of Sauvie Inc., a New Jersey-based biotech company developing transformational cancer therapies. Sauvie Inc. signed an exclusive license with Rutgers to form Sauvie BiKE, LLC.

 

headshot of Adam Gormley

Adam Gormley, PhD

Associate Professor of Biomedical Engineering, Rutgers
Co-founder, Plexymer, Inc.

Adam is an Associate Professor of Biomedical Engineering at Rutgers University, Executive Editor of Advanced Drug Delivery Reviews, and co-founder of Rutgers startup Plexymer, Inc. In January 2017, Adam started the Gormley Lab which seeks to develop bioactive nanobiomaterials using robotics and artificial intelligence. He is currently the PI of an NIH R35 MIRA Award, an NSF CBET Award, and an NSF Designing Materials to Revolutionize and Engineer our Future (DMREF) Award.